Health Care & Life Sciences » Biotechnology | Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. | Mutual Funds

Mutual Funds that own Halozyme Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BB Biotech AG
8,520,137
5.9%
-105,914
3.78%
03/31/2018
Vanguard Small Cap Index Fund
3,077,238
2.13%
40,478
0.06%
07/31/2018
Vanguard Total Stock Market Index Fund
3,038,929
2.11%
3,680
0.01%
07/31/2018
First Eagle Fund of America
2,704,753
1.87%
-1,146,228
2.54%
04/30/2018
iShares Russell 2000 ETF
2,671,510
1.85%
-1,428
0.1%
09/06/2018
SPDR S&P Biotech ETF
2,345,034
1.63%
6,033
0.74%
09/06/2018
Fidelity Select Biotechnology Portfolio
2,024,450
1.4%
95,400
0.41%
07/31/2018
Vanguard Extended Market Index Fund
1,768,082
1.23%
7,800
0.05%
07/31/2018
Vanguard Small Cap Growth Index Fund
1,747,895
1.21%
19,469
0.13%
07/31/2018
Invesco Small Cap Growth Fund
1,701,178
1.18%
9,397
0.95%
06/29/2018

About Halozyme Therapeutics

View Profile
Address
11388 Sorrento Valley Road
San Diego California 92121
United States
Employees -
Website http://www.halozyme.com
Updated 07/08/2019
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.